BAGSVAERD, Denmark, April 28 /CNW/ -
Organic Sales Growth of 15% Driven by Victoza(R), NovoRapid(R) and
Sales increased by 15% in Danish kroner and by 11% in local currencies.
Sales of modern insulins increased by 14% (11% in local currencies).
Victoza(R) sales of DKK 1,098 million (growth of 191% in local
Sales of NovoSeven(R) increased by 6% (4% in local currencies).
Sales in North America increased by 16% (14% in local currencies).
Sales in Region China increased by 34% (28% in local currencies).
Gross margin improved by 0.3 percentage points in local currencies,
reflecting a favourable product mix development, but due to a negative
currency effect, the gross margin declined by 0.2 percentage points to
80.1% compared to the first quarter of 2010.
Reported operating profit increased by 24% to DKK 5,418 million.
Measured in local currencies, operating profit increased by
Net profit increased by 23% to DKK 4,073 million. Earnings per share
(diluted) increased by 26% to DKK 7.06.
Novo Nordisk has completed a pre-specified meta-analysis based on the
Degludec phase 3a trial programme. The meta-analysis confirmed that
Degludec is associated with a lower risk of hypoglycaemia compared to
insulin glargine, both on the total number of confirmed hypoglycaemic
events, and on the number of confirmed nocturnal hypoglycaemic events.
Both findings are statistically significant.
The 2011 outlook remains unchanged: sales growth of 8-10% and operating
profit growth of around 15%, both measured in local currencies.
Lars Rebien Sorensen, president and CEO, says: "We are encouraged by the
continued double-digit sales growth driven by Victoza(R) and modern
insulins. It strengthens our confidence in the company's long term
growth prospects despite the near-term impact on sales growth from
healthcare reforms in the US and other major markets, which is
reflected in the 2011 outlook."
Company Announcement no 25 /2011
Read the full announcement in PDF format:
For broadcast standard video supporting this release please visit our
Broadcast room on novonordisk.com - Media
SOURCE Novo Nordisk A/S
For further information:
Media: Mike Rulis, Tel: (+45)4442-3573, email@example.com; In North America, Ken Inchausti, Tel: (+1)609-786-8316, firstname.lastname@example.org